Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.
- GMP manufacturing underway with PI Health Sciences
- Supports pivotal Marburg efficacy study under FDA Animal Rule
- Existing Galidesivir stock to back dose optimisation trials
- Establishes infrastructure for regulatory approval and biodefence procurement
- Positions Galidesivir for broader outbreak response including Ebola
GMP Manufacturing Launches Late-Stage Development
Island Pharmaceuticals (ASX:ILA) has commenced GMP manufacturing of its broad-spectrum antiviral Galidesivir, partnering with global contract manufacturer PI Health Sciences (PIHS) to produce clinical-grade material tailored for a pivotal Marburg Virus Disease study. This manufacturing campaign is designed to validate and scale production to meet the rigours of late-stage development, a crucial step before potential US FDA submission under the Animal Rule pathway.
While Island already holds sufficient Galidesivir inventory for planned dose optimisation studies, the new GMP-grade product will underpin the pivotal efficacy trial expected to form the cornerstone of regulatory filings. The campaign also includes analytical method validation, stability studies, and reference standard preparation, establishing the quality and regulatory framework needed for future human safety studies and government procurement opportunities.
Strategic Flexibility for Biodefence and Outbreak Response
Beyond supporting the Marburg program, the availability of GMP-grade Galidesivir enhances Island’s ability to engage rapidly with biodefence and emerging infectious disease initiatives. The drug has demonstrated antiviral activity across over 20 RNA viruses, including Ebola, MERS, and Zika, positioning it as a versatile countermeasure amid renewed global focus on pandemic preparedness and biodefence.
Recent outbreaks, such as the Bundibugyo Ebola strain, underscore the strategic importance of maintaining access to clinical-grade antiviral supplies. Island’s CEO Dr David Foster highlighted that this manufacturing milestone transitions Galidesivir from a legacy asset into an actively advancing biodefence program, assembling the critical components required for regulatory engagement and potential government stockpiling.
Global Manufacturing Partner with Regulatory Expertise
PIHS operates GMP-compliant facilities across Europe and Asia, specialising in active pharmaceutical ingredient development and manufacturing for regulated markets. Their extensive experience with clinical development and commercialisation supports Island’s ambitions to scale Galidesivir production to meet late-stage clinical and biodefence demands.
This collaboration aligns with Island’s broader strategy to position Galidesivir as a biodefence countermeasure for high-consequence viral threats, complementing recent moves to strengthen US regulatory ties and trial capabilities. The company’s ongoing regulatory pathway development and access to non-human primates for efficacy studies further solidify its progression toward FDA submission.
Bottom Line?
The GMP manufacturing milestone sets Island Pharmaceuticals on a firmer path to regulatory submission and biodefence readiness, but clinical trial outcomes and government procurement deals will be critical next steps.
Questions in the middle?
- How will the pivotal Marburg study results influence FDA approval timelines?
- What government procurement opportunities might emerge from this manufacturing capability?
- Could Galidesivir’s broad antiviral profile lead to expanded indications beyond filoviruses?